FDA Modernization Act 3.0
Latest Action
Held at the desk.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The FDA Modernization Act 3.0 is a Senate bill from the 118th Congress aimed at updating and reforming the Food and Drug Administration's regulatory framework. Although the official summary and full text are not available, the bill is categorized under the health policy area and appears to focus on modernizing FDA processes. The latest recorded action is that the bill was held at the desk on December 16, 2024, and the bill status is marked as failed or expired.
This bill intended to modernize FDA regulations but did not advance beyond being held at the desk and ultimately expired without passage.
- The bill is titled FDA Modernization Act 3.0 and was introduced in the Senate during the 118th Congress.
- No official summary or full text is publicly available, limiting detailed analysis of specific provisions.
- The bill was last recorded as held at the desk on December 16, 2024, and is now considered failed or expired.
['Potential beneficiaries would likely include pharmaceutical companies, medical device manufacturers, healthcare providers, and patients who rely on FDA-regulated products, assuming the bill aimed to streamline or update FDA regulatory processes.']
['Lack of publicly available bill text and summary limits understanding of implementation challenges or cost implications.', 'Without detailed provisions, it is unclear how authority or oversight mechanisms might be affected or altered.', 'The failure to advance past being held at the desk suggests possible legislative or procedural hurdles.']
The bill was introduced in the Senate during the 118th Congress and is part of ongoing efforts to update FDA regulatory frameworks. The bill did not progress beyond being held at the desk and is now expired, indicating it did not receive further legislative consideration or votes.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, modernization of FDA regulations could influence the speed and efficiency of product approvals, potentially affecting innovation and public health outcomes.', 'Failure to pass may maintain the status quo in FDA regulatory processes, impacting stakeholders seeking regulatory reform.']
The absence of an official summary and full bill text restricts transparency and public oversight. The bill's failure to progress beyond being held at the desk highlights the importance of tracking procedural status to understand legislative momentum. Future efforts to modernize FDA regulations would benefit from clear, accessible documentation to facilitate informed public and stakeholder engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.